PLATFORM INTRODUCTION
Relying on its own technological iteration and innovation, as well as the upgraded propr<ietary platform technology, Siran Bio has established a com✔prehensive siRNA drug development technology platform. This platf orm independently encompasses the entire process of siRNA drug develo÷pment, including sequence discovery, siRNA design, nucleic acid synthesis, stabilization§ modification, off-target modification, as well as intrahepatic delivery and du↕al-target platforms. These capabilities ensure high qual£ity, efficiency, a high success rate, and a continuous output of innovative pipeline.
The company has rich experience in siRNA design, and ≠can quickly complete the sequence design of research targets through the use of bioinformatics analysis and auxiliary design. The company has established a complete high-throughput screening platform for in vitro and in viv±o test, which can complete the selection of optimal sequence targets within 3 m×onths.
The company has developed a proprietary chemical modification platform that can signi×ficantly enhance the safety profile of siRNA while §preserving its efficiency. This platform mitigates the off-tar→get effect and improving metabolic stability, thereby ensuring the safety, efficacy, and dur€ation of siRNA drugs.
The company has established a complete solid-phase synthesis sy≤stem for nucleic acids, which can efficiently complete the synthesis, purification, and analysis of siRNA molecules, and efficiently support pl>atform technology and pipeline research and development.
Scan to follow us
Phone：0086-512-65295956
Email：info@siranbio.com
